Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 2
2007 1
2008 1
2009 3
2012 1
2013 7
2014 4
2015 5
2016 3
2017 1
2018 2
2019 3
2020 2
2021 2
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.
Tapia-Galisteo A, Sánchez-Rodríguez I, Narbona J, Iglesias-Hernández P, Aragón-García S, Jiménez-Reinoso A, Compte M, Khan S, Tsuda T, Chames P, Lacadena J, Álvarez-Vallina L, Sanz L. Tapia-Galisteo A, et al. Among authors: compte m. Oncoimmunology. 2024 Apr 13;13(1):2338558. doi: 10.1080/2162402X.2024.2338558. eCollection 2024. Oncoimmunology. 2024. PMID: 38623463 Free PMC article.
Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2.
Lázaro-Gorines R, Pérez P, Heras-Murillo I, Adán-Barrientos I, Albericio G, Astorgano D, Flores S, Luczkowiak J, Labiod N, Harwood SL, Segura-Tudela A, Rubio-Pérez L, Nugraha Y, Shang X, Li Y, Alfonso C, Adipietro KA, Abeyawardhane DL, Navarro R, Compte M, Yu W, MacKerell AD Jr, Sanz L, Weber DJ, Blanco FJ, Esteban M, Pozharski E, Godoy-Ruiz R, Muñoz IG, Delgado R, Sancho D, García-Arriaza J, Álvarez-Vallina L. Lázaro-Gorines R, et al. Among authors: compte m. Adv Sci (Weinh). 2023 Dec;10(34):e2304818. doi: 10.1002/advs.202304818. Epub 2023 Oct 20. Adv Sci (Weinh). 2023. PMID: 37863812 Free PMC article.
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Rubio-Pérez L, Lázaro-Gorines R, Harwood SL, Compte M, Navarro R, Tapia-Galisteo A, Bonet J, Blanco B, Lykkemark S, Ramírez-Fernández Á, Ferreras-Gutiérrez M, Domínguez-Alonso C, Díez-Alonso L, Segura-Tudela A, Hangiu O, Erce-Llamazares A, Blanco FJ, Santos C, Rodríguez-Peralto JL, Sanz L, Álvarez-Vallina L. Rubio-Pérez L, et al. Among authors: compte m. Oncoimmunology. 2023 Apr 24;12(1):2205336. doi: 10.1080/2162402X.2023.2205336. eCollection 2023. Oncoimmunology. 2023. PMID: 37114242 Free PMC article.
Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.
Hangiu O, Compte M, Dinesen A, Navarro R, Tapia-Galisteo A, Mandrup OA, Erce-Llamazares A, Lázaro-Gorines R, Nehme-Álvarez D, Domínguez-Alonso C, Harwood SL, Alfonso C, Blanco B, Rubio-Pérez L, Jiménez-Reinoso A, Díez-Alonso L, Blanco FJ, Sanz L, Howard KA, Álvarez-Vallina L. Hangiu O, et al. Among authors: compte m. iScience. 2022 Aug 17;25(9):104958. doi: 10.1016/j.isci.2022.104958. eCollection 2022 Sep 16. iScience. 2022. PMID: 36072551 Free PMC article.
Applications of trimerbodies in cancer immunotherapy.
Compte M, Sanz L, Álvarez-Vallina L. Compte M, et al. Int Rev Cell Mol Biol. 2022;369:71-87. doi: 10.1016/bs.ircmb.2022.03.008. Epub 2022 May 16. Int Rev Cell Mol Biol. 2022. PMID: 35777865
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.
Blanco B, Ramírez-Fernández Á, Bueno C, Argemí-Muntadas L, Fuentes P, Aguilar-Sopeña Ó, Gutierrez-Agüera F, Zanetti SR, Tapia-Galisteo A, Díez-Alonso L, Segura-Tudela A, Castellà M, Marzal B, Betriu S, Harwood SL, Compte M, Lykkemark S, Erce-Llamazares A, Rubio-Pérez L, Jiménez-Reinoso A, Domínguez-Alonso C, Neves M, Morales P, Paz-Artal E, Guedan S, Sanz L, Toribio ML, Roda-Navarro P, Juan M, Menéndez P, Álvarez-Vallina L. Blanco B, et al. Among authors: compte m. Cancer Immunol Res. 2022 Apr 1;10(4):498-511. doi: 10.1158/2326-6066.CIR-21-0853. Cancer Immunol Res. 2022. PMID: 35362043 Free PMC article.
Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer.
Tapia-Galisteo A, Sánchez Rodríguez Í, Aguilar-Sopeña O, Harwood SL, Narbona J, Ferreras Gutierrez M, Navarro R, Martín-García L, Corbacho C, Compte M, Lacadena J, Blanco FJ, Chames P, Roda-Navarro P, Álvarez-Vallina L, Sanz L. Tapia-Galisteo A, et al. Among authors: compte m. Oncoimmunology. 2022 Feb 7;11(1):2034355. doi: 10.1080/2162402X.2022.2034355. eCollection 2022. Oncoimmunology. 2022. PMID: 35154908 Free PMC article.
An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
Compte M, Harwood SL, Erce-Llamazares A, Tapia-Galisteo A, Romero E, Ferrer I, Garrido-Martin EM, Enguita AB, Ochoa MC, Blanco B, Oteo M, Merino N, Nehme-Álvarez D, Hangiu O, Domínguez-Alonso C, Zonca M, Ramírez-Fernández A, Blanco FJ, Morcillo MA, Muñoz IG, Melero I, Rodriguez-Peralto JL, Paz-Ares L, Sanz L, Alvarez-Vallina L. Compte M, et al. Clin Cancer Res. 2021 Jun 1;27(11):3167-3177. doi: 10.1158/1078-0432.CCR-20-4625. Epub 2021 Mar 30. Clin Cancer Res. 2021. PMID: 33785484
43 results